Literatur
Alonso-Ruiz A, Pijoan JI et al (2008) Tumor necrosis factor alpha drugs in rheumatoid arthritis: Systematic review and metaanalysis of efficacy and safety. BMC Musculoskelet Disord 9:52
Askling J, Bongartz T (2008) Malignancy and biologic therapy in rheumatoid arthritis. Curr Opin Rheumatol 20:334–339
Askling J, Baecklund E et al (2008) Anti-TNF therapy in RA and risk of malignant lymphomas relative risks and time-trends in the Swedish Biologics Register. Ann Rheum Dis [Epub ahead of print, May 8]
Askling J, Fored C M et al (2005) Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis 64:1421–1426
Baecklund E, Iliadou A et al (2006) Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 54:692–701
Bongartz T, Sutton A J et al (2006) Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: Systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295:2275–2285
Bielack S (2007) Leukämien und maligne Knochentumoren. In: Wagner N, Dannecker G (Hrsg) Pädiatrische Rheumatologie, Springer, Berlin Heidelberg New York Tokyo
Brown S L, Greene M H et al (2002) Tumor necrosis factor antagonist therapy and lymphoma development: Twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 46:3151–3158
Cabral DA, Tucker LB (1999) Malignancies in children who initially present with rheumatic complaints. J Pediatr 134:53–57
Carmona L, Descalzo MA et al (2007) All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists. Ann Rheum Dis 66:880–885
Gartlehner G, Hansen R A et al (2008) Biologics for the treatment of juvenile idiopathic arthritis: A systematic review and critical analysis of the evidence. Clin Rheumatol 27:67–76
Geborek P, Bladstrom A et al (2005) Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis 64:699–703
Goncalves M, Terreri MTRA, Barbosa CMPL et al (2005) Diangosis of malignancies in children with musculoskeletal complaints. Sao Paulo Med J 123:21–23
Horneff G, De Bock F et al (2008) Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA). Preliminary data from the german JIA Registry. Ann Rheum Dis [Epub ahead of print, April 15]
Imundo L (2008) Hodgkin’s lymphoma associated with anti-TNF use in juvenile idiopathic arthritis: Supplemental case report. J Rheumatol 35:1681
Lovell DJ, Reiff A et al (2008) Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum 58:1496–1504
Moreland LW, Weinblatt ME et al (2006) Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experience. J Rheumatol 33:854–861
Prince FH, Twilt M et al (2008) Long-term follow-up on effectiveness and safety of etanercept in JIA: the Dutch national register. Ann Rheum Dis [Epub ahead of print, April 15]
Schiff MH, Burmester GR et al (2006) Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis 65:889–894
Schiff M, Keiserman M et al (2008) Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: A phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 67:1096–1103
Setoguchi S, Solomon DH et al (2006) Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum 54:2757–2764
Trapani S, Grisolia F, Simonini G et al (2000) Incidence of occult cancer in children presenting with musculoskeletal symptoms: A 10-year survey in a pediatric rheumatology unit. Semin Arthritis Rheum 29:348–359
Wolfe F, Michaud K (2007) Biologic treatment of rheumatoid arthritis and the risk of malignancy: Analyses from a large US observational study. Arthritis Rheum 56:2886–2895
Yildirim-Toruner C, Kimura Y et al (2008) Hodgkin’s lymphoma and tumor necrosis factor inhibitors in juvenile idiopathic arthritis. J Rheumatol 35:1680–1681
Interessenkonflikt
Der korrespondierende Autor weist auf folgende Beziehungen hin: Forschungsförderung durch Wyeth, Abbott-Pharma.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hospach, T., Haas, J., Huppertz, H. et al. Stellungnahme der Gesellschaft für Kinder- und Jugendrheumatologie zur Meldung der US-Food and Drug Administration (FDA) über Fälle von Malignomen bei Anti-TNF-behandelten Patienten. Z. Rheumatol. 68, 162–164 (2009). https://doi.org/10.1007/s00393-008-0426-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00393-008-0426-y